Format

Send to

Choose Destination
Oncologist. 2001;6(6):506-16.

The development of camptothecin analogs in childhood cancers.

Author information

1
Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA. lbomgaars@txccc.org

Abstract

Camptothecin analogs, agents that target the intranuclear enzyme topoisomerase I, represent a promising new class of anticancer drugs for the treatment of childhood cancer. In preclinical studies, camptothecins, such as topotecan and irinotecan, are highly active against a variety of pediatric malignancies including neuroblastomas, rhabdomyosarcomas, gliomas, and medulloblastomas. In this paper, we review the status of completed and ongoing clinical trials and pharmacokinetic studies of camptothecin analogs in children. These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer.

PMID:
11743213
DOI:
10.1634/theoncologist.6-6-506
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center